Prelude Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-8,833
| Closed | -$83K | – | 2261 |
|
|
2020
Q3 | $83K | Sell |
8,833
-1,294
| -13% | -$12.3K | ﹤0.01% | 974 |
|
|
2020
Q2 | $77K | Hold |
10,127
| – | – | ﹤0.01% | 1030 |
|
|
2020
Q1 | $63K | Buy |
+10,127
| New | +$89.2K | ﹤0.01% | 703 |
|
|
2019
Q3 | – | Sell |
-897
| Closed | -$9K | – | 2232 |
|
|
2019
Q2 | $9K | Buy |
+897
| New | +$9.68K | ﹤0.01% | 1431 |
|
|
2019
Q1 | – | Sell |
-3,100
| Closed | -$47K | – | 2353 |
|
|
2018
Q4 | $47K | Buy |
+3,100
| New | +$59.1K | ﹤0.01% | 1127 |
|
|
2018
Q1 | – | Sell |
-559
| Closed | -$7K | – | 1817 |
|
|
2017
Q4 | $7K | Sell |
559
-1,900
| -77% | -$28.6K | ﹤0.01% | 1245 |
|
|
2017
Q3 | $45K | Buy |
2,459
+2,059
| +515% | +$38.4K | ﹤0.01% | 1135 |
|
|
2017
Q2 | $7K | Sell |
400
-3,264
| -89% | -$64.7K | ﹤0.01% | 1446 |
|
|
2017
Q1 | $83K | Sell |
3,664
-25,443
| -87% | -$609K | 0.01% | 847 |
|
|
2016
Q4 | $1.01M | Buy |
29,107
+8,007
| +38% | +$239K | 0.12% | 204 |
|
|
2016
Q3 | $517K | Buy |
21,100
+9,691
| +85% | +$242K | 0.05% | 307 |
|
|
2016
Q2 | $273K | Buy |
11,409
+10,729
| +1,578% | +$246K | 0.04% | 411 |
|
|
2016
Q1 | $16K | Buy |
+680
| New | +$16.1K | ﹤0.01% | 1138 |
|
|
2015
Q4 | – | Sell |
-1,400
| Closed | -$56K | – | 1778 |
|
|
2015
Q3 | $56K | Buy |
1,400
+1,100
| +367% | +$68.3K | 0.01% | 1029 |
|
|
2015
Q2 | $21K | Buy |
+300
| New | +$18.9K | ﹤0.01% | 1357 |
|
|
2014
Q4 | – | Sell |
-6,200
| Closed | -$198K | – | 2250 |
|
|
2014
Q3 | $198K | Sell |
6,200
-1,000
| -14% | -$21.3K | 0.03% | 719 |
|
|
2014
Q2 | $149K | Buy |
7,200
+3,900
| +118% | +$72.1K | 0.02% | 869 |
|
|
2014
Q1 | $64K | Buy |
+3,300
| New | +$70.1K | 0.01% | 1199 |
|
|
2013
Q4 | – | Sell |
-3,408
| Closed | -$73K | – | 2030 |
|
|
2013
Q3 | $73K | Buy |
+3,408
| New | +$80.5K | 0.01% | 877 |
|
Prelude Capital Management's AMAG Position: Q4 2020 in Review
Prelude Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 8,833 shares — an estimated $83K sold.
Prelude Capital Management first reported a position in AMAG in Q3 2013 and held it in 19 quarters. The position peaked at $1.01M in Q4 2016. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Prelude Capital Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Prelude Capital Management sold 8,833 AMAG Pharmaceuticals shares in Q4 2020, an estimated $83K.
- Prelude Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2013 and held it in 19 quarters.
- Prelude Capital Management's AMAG Pharmaceuticals position peaked at $1.01M in Q4 2016.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.